Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GHRS NASDAQ:IMCR NASDAQ:NTLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHRSGH Research$22.12$17.78$10.66▼$24.66$1.52B1.27213,905 shs350,785 shsIMCRImmunocore$28.83$30.07$27.56▼$40.71$1.46B0.74306,307 shs689,631 shsNTLAIntellia Therapeutics$12.60$13.53$6.83▼$28.25$1.76B1.939.58 million shs3.19 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHRSGH Research0.00%+3.41%+9.23%+43.45%+98.03%IMCRImmunocore0.00%+2.78%-1.60%-12.45%-7.48%NTLAIntellia Therapeutics0.00%-7.83%-7.56%-4.26%+37.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHRSGH Research$22.12$17.78$10.66▼$24.66$1.52B1.27213,905 shs350,785 shsIMCRImmunocore$28.83$30.07$27.56▼$40.71$1.46B0.74306,307 shs689,631 shsNTLAIntellia Therapeutics$12.60$13.53$6.83▼$28.25$1.76B1.939.58 million shs3.19 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHRSGH Research0.00%+3.41%+9.23%+43.45%+98.03%IMCRImmunocore0.00%+2.78%-1.60%-12.45%-7.48%NTLAIntellia Therapeutics0.00%-7.83%-7.56%-4.26%+37.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHRSGH Research 2.73Moderate Buy$40.3882.53% UpsideIMCRImmunocore 2.60Moderate Buy$57.75100.31% UpsideNTLAIntellia Therapeutics 2.35Hold$20.2560.71% UpsideCurrent Analyst Ratings BreakdownLatest IMCR, GHRS, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026GHRSGH Research HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $65.005/15/2026GHRSGH Research CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/15/2026GHRSGH Research Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $35.005/15/2026GHRSGH Research Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$42.00 ➝ $39.005/13/2026NTLAIntellia Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$13.00 ➝ $17.005/13/2026NTLAIntellia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $25.005/12/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$58.00 ➝ $49.005/12/2026NTLAIntellia Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$12.005/7/2026IMCRImmunocore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Strong-Buy4/28/2026NTLAIntellia Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$8.00 ➝ $9.004/28/2026NTLAIntellia Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHRSGH ResearchN/AN/AN/AN/A$4.51 per shareN/AIMCRImmunocore$400.02M3.65N/AN/A$7.77 per share3.71NTLAIntellia Therapeutics$67.67M26.02N/AN/A$4.44 per share2.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHRSGH Research-$48.26M-$0.92N/AN/AN/AN/A-19.36%-18.73%8/6/2026 (Estimated)IMCRImmunocore-$35.51M-$0.55N/A262.09N/A-6.68%-7.07%-2.55%8/6/2026 (Estimated)NTLAIntellia Therapeutics-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)Latest IMCR, GHRS, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026GHRSGH Research-$0.27-$0.31-$0.04-$0.31N/AN/A5/11/2026Q1 2026NTLAIntellia Therapeutics-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million5/6/2026Q1 2026IMCRImmunocore-$0.26$0.25+$0.51$0.25$145.20 million$106.68 million3/6/2026Q4 2025GHRSGH Research-$0.29-$0.23+$0.06-$0.23N/AN/A2/26/2026Q4 2025NTLAIntellia Therapeutics-$0.99-$0.83+$0.16-$0.83$12.17 million$23.02 million2/25/2026Q4 2025IMCRImmunocore-$0.28-$0.60-$0.32-$0.60$145.48 million$104.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGHRSGH ResearchN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHRSGH ResearchN/A34.1334.13IMCRImmunocore1.004.184.15NTLAIntellia TherapeuticsN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHRSGH Research56.90%IMCRImmunocore84.50%NTLAIntellia Therapeutics88.77%Insider OwnershipCompanyInsider OwnershipGHRSGH Research41.60%IMCRImmunocore10.10%NTLAIntellia Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHRSGH Research1068.61 million40.07 millionOptionableIMCRImmunocore32050.69 million45.58 millionOptionableNTLAIntellia Therapeutics600139.72 million135.39 millionOptionableIMCR, GHRS, and NTLA HeadlinesRecent News About These CompaniesIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Hold" from AnalystsMay 20, 2026 | americanbankingnews.comCan Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?May 19, 2026 | zacks.comIntellia Therapeutics (NASDAQ:NTLA) Trading 7.3% Higher - Here's What HappenedMay 17, 2026 | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) Lowered to Sell Rating by Wall Street ZenMay 16, 2026 | americanbankingnews.comHC Wainwright Has Positive Outlook for NTLA Q2 EarningsMay 15, 2026 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This YearMay 14, 2026 | finance.yahoo.comWells Fargo Remains a Hold on Intellia Therapeutics (NTLA)May 14, 2026 | theglobeandmail.comResearch Analysts Issue Forecasts for NTLA Q1 EarningsMay 14, 2026 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $25.00 by Analysts at HC WainwrightMay 14, 2026 | americanbankingnews.comWedbush Remains a Hold on Intellia Therapeutics (NTLA)May 13, 2026 | theglobeandmail.comIntellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comNTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in FocusMay 12, 2026 | zacks.comIntellia Therapeutics (NASDAQ:NTLA) Announces Earnings ResultsMay 11, 2026 | marketbeat.comIntellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue EstimatesMay 11, 2026 | zacks.comIntellia Therapeutics Announces First Quarter 2026 Financial Results and Business UpdatesMay 11, 2026 | globenewswire.comCanal Insurance CO Invests $899,000 in Intellia Therapeutics, Inc. $NTLAMay 8, 2026 | marketbeat.comAssessing Intellia Therapeutics (NTLA) Valuation After Positive Phase 3 HAELO Results And BLA Submission For Lonvo ZMay 7, 2026 | finance.yahoo.comIntellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?May 7, 2026 | zacks.comIntellia Therapeutics (NTLA) Projected to Post Earnings on ThursdayMay 7, 2026 | marketbeat.comIntellia Therapeutics to Participate in Upcoming Investor ConferencesMay 5, 2026 | globenewswire.comNTLA Q2 EPS Increased by Brookline Capital MarketsMay 4, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMCR, GHRS, and NTLA Company DescriptionsGH Research NASDAQ:GHRS$22.12 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$22.42 +0.31 (+1.38%) As of 05/22/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Immunocore NASDAQ:IMCR$28.83 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$28.92 +0.10 (+0.33%) As of 05/22/2026 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Intellia Therapeutics NASDAQ:NTLA$12.60 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$12.52 -0.08 (-0.63%) As of 05/22/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
